Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

CHF 5259

Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.

DRUG

Placebo

Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.

Trial Locations (29)

Unknown

Chiesi Clinical Trial Site 1017, Sevlievo

Chiesi Clinical Trial Site 1010, Sofia

Chiesi Clinical Trial Site 1011, Sofia

Chiesi Clinical Trial Site 1014, Sofia

Chiesi Clinical Trial Site 1015, Sofia

Chiesi Clinical Trial Site 1016, Sofia

Chiesi Clinical Trial Site 1012, Stara Zagora

Chiesi Clinical Trial Site 1013, Troyan Municipality

Chiesi Clinical Trial Site 2024, Berlin

Chiesi Clinical Trial Site 2028, Berlin

Chiesi Clinical Trial Site 2027, Hamburg

Chiesi Clinical Trial Site 2026, Leipzig

Chiesi Clinical Trial Site 2023, Magdeburg

Chiesi Clinical Trial Site 2021, Radebeul

Chiesi Clinical Trial Site 2022, Witten

Chiesi Clinical Trial Site 3039, Bydgoszcz

Chiesi Clinical Trial Site 3032, Katowice

Chiesi Clinical Trial Site 3035, Krakow

Chiesi Clinical Trial Site 3037, Lubin

Chiesi Clinical Trial Site 3031, Ostrowiec Świętokrzyski

Chiesi Clinical Trial Site 3033, Oświęcim

Chiesi Clinical Trial Site 3038, Rzeszów

Chiesi Clinical Trial Site 3034, Tarnów

Chiesi Clinical Trial Site 3030, Wroclaw

Chiesi Clinical Trial Site 3036, Zgierz

Chiesi Clinical Trial Site 4042, London

Chiesi Clinical Trial Site 4041, Manchester

D-22927

Site 2020 - Pulmonary Research Institute at Hospital Grosshansdorf, Großhansdorf

SW7 2AZ

Site 4040 - Royal Brompton and Harefield NHS Foundation Trust; South Kensington Campus, London

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02189577 - Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients | Biotech Hunter | Biotech Hunter